DelistingApr 29, 2026, 08:07 AM
SGMO Delisted from Nasdaq, to Trade on OTCQB Venture Market May 5
AI Summary
Sangamo Therapeutics, Inc. (SGMO) announced its common stock will transition from The Nasdaq Capital Market to the OTCQB Venture Market, effective May 5, 2026. This follows a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, leading to delisting. Sangamo intends to appeal the delisting but trading on Nasdaq will be suspended. The company has secured approval for its stock to be quoted on the OTCQB Venture Market under its existing symbol and does not expect material impacts to its business. Sangamo continues to pursue capital raising opportunities and negotiate potential business development transactions.
Key Highlights
- SGMO common stock to transition from Nasdaq Capital Market to OTCQB Venture Market.
- Trading on OTCQB Venture Market expected to begin Tuesday, May 5, 2026, under existing symbol SGMO.
- Delisting from Nasdaq due to non-compliance with minimum bid price requirement.
- Sangamo intends to request a hearing from Nasdaq to appeal the delisting determination.
- Company remains focused on raising additional capital and assessing strategic options.
- Sangamo is negotiating multiple potential business development transactions.